Zacks Investment Research on MSN
EU approves expanded use of ABBV's Tepkinly in follicular lymphoma
AbbVie ABBV announced that the European Commission (EC) approved the expanded use of Tepkinly (epcoritamab) for the relapsed ...
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the ...
Peter Voorhees, MD, of Atrium Health Levine Cancer Institute, discusses data from the MonumenTAL-3 study (NCT05455320), a ...
A single infusion of chimeric antigen receptor T-cell (CAR-T) therapy induced complete response or remission in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small ...
By Dennis Thompson HealthDay ReporterWEDNESDAY, June 3, 2026 (HealthDay News) — A recently approved cancer immunotherapy can put nearly two-thirds of people with relapsed multiple myeloma into ...
Multiple myeloma is considered to be relapsed if symptoms of the disease appear after a time of improvement. It’s considered to be refractory when it gets worse even though it’s being treated. To ...
The American Society of Hematology (ASH) released guidelines on frontline management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed ...
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies ...
Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R 2 ) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results